Your Article Summary
See Latest ArticlesA randomized, double-blind, placebo-controlled phase 3 study of the relative efficacy and tolerability of tapentadol IR and oxycodone IR for acute pain
Current Medical Research and Opinion, 06/29/09
Daniels S et al. - Clinically meaningful and statistically significant improvements were observed with tapentadol IR 50mg and 75mg compared with placebo for the relief of moderate-to-severe acute pain after orthopedic surgery. Tapentadol IR 50mg and 75mg were non-inferior to oxycodone HCl IR 10mg for the treatment of acute pain based on the primary efficacy endpoint of SPID48 and the pre-specified margin of 48 points.
Today in Drug Interactions...keeping you current
Receive free subspecialty "5-minute updates" via email
Subcutaneous Sumatriptan Pharmacokinetics: Delimiting the Monoamine Oxidase Inhibitor Effect
Headache: The Journal of Head and Face Pain, 12/08/09
Treatment persistence in and cost of therapy for patients with chronic hepatitis C: Peginterferon alfa-2a plus ribavirin versus peginterferon alfa-2b plus ribavirin
American Journal of Health-System Pharmacy, 12/08/09
Potential interactions between cilostazol and probucol: A two-part, single-dose, open-label study in healthy Korean male volunteers
Clinical Therapeutics, 12/07/09
Today in Other Drugs...keeping you current
Receive free subspecialty "5-minute updates" via email
Pioglitazone and mechanisms of CV protection
QJM: An International Journal of Medicine, 12/08/09
Inflammatory breast cancer: what are the treatment options
Expert Opinion in Pharmacotherapy, 12/08/09
Linagliptin, a xanthine-based dipeptidyl peptidase-4 inhibitor with an unusual profile for the treatment of type 2 diabetes
Expert Opinion on Investigational Drugs, 12/08/09